The Combating Illicit Xylazine Act aims to control the use of xylazine, a sedative mainly used in animals, by classifying it as a Schedule III controlled substance. This means it is recognized as having medical use but also a potential for abuse. The bill imposes criminal penalties for illegal manufacturing and distribution of xylazine and requires tracking of its transactions. It allows certain exemptions for legal use in veterinary and animal-control settings. Additionally, it mandates the DEA to report on the impact of illicit xylazine use and trafficking in the U.S.
H.R. 1266 was introduced in the 119th Congress by Jimmy Panetta (Democrat) and is currently listed as “Passed House”. It is classified under the Crime and Law Enforcement policy area, one of 235 bills in that area we track this Congress.
Jimmy Panetta is the sponsor of 9 bills in our database this Congress, so H.R. 1266 is part of a broader legislative agenda rather than a one-off proposal.
Our conflict-of-interest analysis rates H.R. 1266 2/10 (low risk), higher than 76% of analyzed bills; the average in Crime and Law Enforcement is 2/10.
Supporters of the Combating Illicit Xylazine Act commend it as a necessary step to address the rising issue of xylazine mixed with fentanyl, which poses serious health risks. The bill is seen as a proactive measure to enhance public safety and improve drug monitoring systems, ultimately aiming to reduce the prevalence of drug-related overdoses and trafficking.
Critics of the Combating Illicit Xylazine Act argue that the bill may not effectively address the root causes of drug abuse and trafficking. Some believe that regulating xylazine could hinder legitimate veterinary practices and that the focus should instead be on broader drug policy reforms. Additionally, concerns have been raised about the potential for increased penalties leading to more incarceration without addressing addiction treatment.
The analysis of H.R. 1266, the Combating Illicit Xylazine Act, reveals no direct industry overlaps between the bill's subject matter and the top donor industries of its sponsor, Jimmy Panetta. His top donors include Health Professionals, contributing $120 million, and Retired individuals, contributing $37.5 million. Given that the bill addresses issues related to illicit substances, the absence of donors from the pharmaceutical or substance abuse treatment sectors suggests a low risk of conflicts of interest. Voters should be aware that while the financial support from Health Professionals is substantial, it does not directly influence the legislative agenda concerning illicit drugs, as there are no relevant ties to the bill's focus on xylazine, a synthetic opioid. Therefore, the potential for conflicts arising from financial contributions is minimal.
Top industries funding Jimmy Panetta, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
What does H.R. 1266 do?
The Combating Illicit Xylazine Act aims to control the use of xylazine, a sedative mainly used in animals, by classifying it as a Schedule III controlled substance. This means it is recognized as having medical use but also a potential for abuse. The bill imposes criminal penalties for illegal manufacturing and distribution of xylazine and requires tracking of its transactions. It allows certain…
Has H.R. 1266 received a floor vote?
No roll-call vote on H.R. 1266 is recorded in our database yet. Its current status is “Passed House”.
Does H.R. 1266 have a conflict of interest?
Our conflict-of-interest analysis rates H.R. 1266 2/10 (low risk), higher than 76% of analyzed bills; the average in Crime and Law Enforcement is 2/10. This score reflects overlap between the sponsor’s campaign funding, lobbying activity, and the industries the bill affects. It is a transparency indicator, not an accusation.
What is the status of H.R. 1266?
H.R. 1266 is currently “Passed House” as of our last update on September 16, 2026.
Who sponsored H.R. 1266?
H.R. 1266 was sponsored by Jimmy Panetta (Democrat).
